<DOC>
	<DOCNO>NCT02258555</DOCNO>
	<brief_summary>This study evaluate safety tolerability GS-9901 monotherapy adult follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) . The study also characterize pharmacokinetic ( PK ) profile GS-9901 , determine appropriate dose regimen GS-9901 use future clinical trial , evaluate efficacy GS-9901 monotherapy adult FL , MZL , CLL , SLL .</brief_summary>
	<brief_title>Safety , Pharmacodynamics , Pharmacokinetics , Efficacy GS-9901 Adults With Relapsed Refractory Follicular Lymphoma , Marginal Zone Lymphoma , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Diagnosis FL , MZL , SLL , CLL ( meet International Workshop CLL [ IWCLL ] Criteria , 2008 ) document medical record histology base criterion establish World Health Organization FL Grades 1 , 2 , 3a SLL absolute lymphocyte count &lt; 5 x 10^9/L initial diagnosis MZL ( splenic , nodal , extranodal ) Prior treatment FL CLL/SLL ≥ 1 prior chemotherapybased immunotherapybased regimen approve therapy available Presence radiographically measurable lymphadenopathy extra nodal lymphoid malignancy All acute toxic effect prior antitumor therapy resolve Grade ≤1 start study therapy ( exception alopecia [ Grade 1 2 permitted ] , bone marrow parameter [ Grade 1 , 2 , 3 permit ) Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 Able provide write informed consent History lymphoid malignancy FL , MZL , SLL , CLL History myelodysplastic syndrome History nonlymphoid malignancy except follow : adequately treat local basal cell squamous cell carcinoma skin , cervical carcinoma situ , superficial bladder cancer , asymptomatic prostate cancer without know metastatic disease requirement therapy require hormonal therapy normal prostatespecific antigen ≥ 1 year prior start study therapy , cancer complete remission ≥ 5 year Evidence ongoing systemic bacterial , fungal , viral infection time start study therapy Ongoing druginduced pneumonitis Ongoing inflammatory bowel disease History prior allogeneic bone marrow progenitor cell solid organ transplantation History prior therapy inhibitor serine/threonine kinase ( AKT ) , Bruton tyrosine kinase ( BTK ) , Janus kinase ( JAK ) , mammalian target rapamycin ( mTOR ) , phosphatidylinositol 3kinase ( PI3K ) , spleen tyrosine kinase ( SYK ) Ongoing immunosuppressive therapy , include systemic corticosteroid treatment lymphoid malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>Follicular lymphoma ( FL )</keyword>
	<keyword>Small Lymphocytic Lymphoma ( SLL )</keyword>
	<keyword>Phosphatidylinositol 3 kinase ( PI3K )</keyword>
	<keyword>Marginal Zone Lymphoma ( MZL )</keyword>
</DOC>